LakeShore Biopharma Receives Revised Proposal for Acquisition and Forms Special Committee for Evaluation
I'm PortAI, I can summarize articles.
LakeShore Biopharma Co., Ltd. has received a revised non-binding acquisition proposal from a consortium led by Oceanpine Capital and Crystal Peak Investment Inc. The offer remains at US$0.86 per share, with the consortium holding 52.1% of shares agreeing to support the proposal. A special committee of independent directors has been formed to evaluate the proposal, but no decisions have been made yet.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments